search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    AC Immune SA

    (NASDAQ:ACIU)

    $3.24

    $0.02

    0.62%

    AC Immune SA Chart

    ACIU Stock Price Today

    AC Immune SA (ACIU) stock rallied over 0.62% intraday to trade at $3.24 a share on NASDAQ. The stock opened with a gain of 10.20% at $3.24 and touched an intraday high of $3.24, rising 0.62% against the last close of $3.22. The stock went to a low of $3.08 during the session.

    Stock Snapshot

    $3.22

    Prev. Close

    244.62 Million

    Market Cap

    $3.08

    Day Low

    $3.24

    Open

    81.89 Million

    Number of Shares

    $3.24

    Day High

    -

    P/E ratio

    -1.00

    EPS (TTM)

    2.12

    Cash Flow per Share

    1.21

    Free Float in %

    2.46

    Book Value

    45,922

    Volume

    AC Immune SA Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$3.24$3.24$3.08$3.2445,900
    2022-06-22$2.94$3.35$2.88$3.22122,000
    2022-06-21$2.65$3.01$2.65$2.99180,600
    2022-06-17$2.3$2.77$2.25$2.6146,800
    2022-06-16$2.06$2.75$2.06$2.35652,500
    2022-06-15$3.15$3.165$2.86$2.8663,500
    2022-06-14$3.17$3.22$3.1$3.1547,700
    2022-06-13$3.41$3.41$3.1$3.1652,400
    2022-06-10$3.37$3.49$3.36$3.4944,700
    2022-06-09$3.5$3.51$3.27$3.418,500

    Contact Details

    Building B
    EPFL Innovation Park
    Lausanne 1015
    Switzerland

    Webiste:ACIU

    41 21 345 91 21

    Company Information

    Employees-

    Beta0.98

    Sales or Revenue0

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

    Frequently Asked Questions

    icon

    What is the current AC Immune SA (ACIU) stock price?

    AC Immune SA (NASDAQ: ACIU) stock price is $3.24 as of the last check on Thursday, June 23. During the trading session, ACIU stock reached the peak price of $3.24 while $3.08 was the lowest point it dropped to.

    icon

    ACIU's industry and sector of operation?

    The NASDAQ listed ACIU is part of Biotechnology industry that operates in the broader Health Care sector. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

    icon

    Who are the executives of ACIU?

    Mr. Joerg Hornstein
    Chief Financial Officer
    Mr. Gautam Maitra Fil. Lic
    Head of Regulatory & External Affairs and Sr. Expert
    Dr. Maria Pihlgren Ph.D.
    Head of Biology
    Dr. Andrea Pfeifer Ph.D.
    Co-Founder, CEO & Director

    icon

    What is the ACIU stock price today?

    ACIU stock traded closed the last session at $3.24, which is $0.02 or 0.62% lower than its previous close of $3.22. ACIU's current trading price is 57.28% lower than its 52-week high of $12.61 where as its distance from 52-week low of 2.06% is -74.31%.

    icon

    How many employees does ACIU have?

    Number of ACIU employees currently stands at -. ACIU operates from Building B, EPFL Innovation Park, Lausanne 1015, Switzerland.

    icon

    Link for ACIU official website?

    Official Webiste of $ACIU is: https://www.acimmune.com

    icon

    How do I contact ACIU?

    ACIU could be contacted at ACIU operates from Building B, EPFL Innovation Park, Lausanne 1015, Switzerland, or at phone #41 21 345 91 21 and can also be accessed through its website.

    icon

    How many shares of ACIU are traded daily?

    ACIU stock volume for the day was 45,922 shares while in the previous session number of ACIU shares traded was 45,900 . The average number of ACIU shares traded daily for last 3 months was 93.24 Thousands.

    icon

    How much did ACIU change today?

    The percentage change in ACIU stock occurred in the recent session was 0.62% while the dollar amount for the price change in ACIU stock was $0.02.

    icon

    What price range ACIU stock been trading in?

    In the recent session, the day high for ACIU stock was $3.24 while the low for ACIU stock touched on the day was $3.08.

    icon

    What is the market cap of ACIU currently?

    The market value of ACIU currently stands at 244.62 Million with its latest stock price at $3.24 and 81.89 Million of its shares outstanding.